How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The search for the male lead in the upcoming show Mukkabaaz is getting increasingly interesting. If all goes as planned, fans of Harshad Chopda might see him headlining the daily soap. While the deal ...

In an engaging post-film interaction, director Harshad Nalawade patiently responded to questions and reactions to his film, Followerwith a smile. The Kannada-Marathi film was screened at Bengaluru’s ...

In July 1991, India dismantled the four-decade-old Licence Raj and embraced economic liberalization. Over the next few months, as unprecedented foreign capital poured in, a peculiar euphoria gripped ...

Follower, the debut feature from Harshad Nalawade, wants to ask the tough questions with grace. At its centre stands Raghu (Raghu Prakash), a radicalised journalist, who follows a local leader and ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — In the year-plus since ...

Recursion Pharmaceuticals doesn't have any products on the market. In fact, none of the company's candidates are currently in phase 3 studies. So, despite the biotech's claims that its AI-powered ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...